AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer's disease.
Shanghai, China. In Curr Neuropharmacol, Feb 2016
Herein, we delineated the catalytic and non-catalytic functions of AChE, and summarized the works of our group and others in research and development of novel AChEI-based multi-target-directed ligands (MTDLs), such as dual binding site AChEIs and multi-target AChEIs inhibiting Aβ aggregation, regulating Aβ procession, antagonizing PAF receptor, scavenging oxygen radical, chelating metal ions, inhibiting MAO-B, blocking NMDA receptor and others.
Parkinson's disease: fewer treatment withdrawals with levodopa.
In Prescrire Int, Dec 2015
In mid-2015, interim results of a randomised trial conducted in the routine care setting, involving 1620 patients with newly diagnosed Parkinson's disease, showed that levodopa was slightly more effective in terms of mobility than dopamine agonists or MAO-B inhibitors, after a median follow-up of 3 years.
Safinamide for symptoms of Parkinson's disease.
Berlin, Germany. In Drugs Today (barc), Nov 2015
Ideal candidates for the balance of these neurotransmitter deficits are compounds like safinamide with broad mechanisms of action such as reversible monoamine oxidase type B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release.
Inhibition and oxygen activation in copper amine oxidases.
Bozeman, United States. In Acc Chem Res, Jun 2015
Inhibition of these enzymes by antifungal or antiprotozoal agents, as well as classic monoamine oxidase (MAO) inhibitors, may contribute to the adverse side effects associated with drug treatment.
Anxiety and IBS revisited: ten years later.
Cluj-Napoca / Kolozsvár, Romania. In Clujul Med, 2014
Out of these 15 articles, 10 articles analyzed the correlation between anxiety-depression status in IBS patients using specific questionnaires, 2 articles analyzed genetic variables in IBS, 1 article analyzed serotonin and monoamine oxidase levels in IBS, 1 article analyzed serum levels of IL-1β and IL-10 in IBS, 1 article analyzed somatostatin and vasoactive intestinal peptide levels in IBS.
Pharmacological treatment of Parkinson disease: a review.
Hamilton, Canada. In Jama, 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.